Founded by Kymab's former leadership team (acquired by Sanofi in 2021)

Quadrucept's QUAD Technology Empowers the Next-Generation of Antibody-based Drugs:-

- Super Antagonists: From new or existing Fab or VHH domains
- Superior “Receptor Bodies”: High avidity receptor-Fc fusion decoy molecules
- Potent Antibody Agonists: Multivalent Fab/VHH receptor clustering
- Improved Target Selectivity: Tetravalent low-affinity high-avidity binding
- Pioneering Bi-Specifics: Flexible formats tailored for every need
- Fc-Multi-valency: Enabling “best-in-class” half-life extension
- “One-Two Punch” ADCs: Avidity-driven targeting-Greater payload capacity
- Simplicity: Highly efficient self-assembly of monomeric building blocks
- Standard Manufacturing: High expression, stability, drug-like properties
- Broad and Early Patent Estate: First to the field – All therapeutic targets

Quadrucept Bio. Ltd.

Org chart

Teams

Offices

Quadrucept Bio. Ltd.

Org chart

Teams

Offices

Related companies